Stock ILMN ILLUMINA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Illumina, Inc.

Equities

ILMN

US4523271090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
122.3 USD +1.02% Intraday chart for Illumina, Inc. +4.13% -12.18%
Apr. 22 Bernstein Adjusts Price Target on Illumina to $129 From $150 MT
Apr. 22 Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 48,766 54,020 59,465 31,806 22,111 19,474 - -
Enterprise Value (EV) 1 46,493 51,732 59,821 32,504 22,546 19,498 18,704 18,189
P/E ratio 49.2 x 83.1 x 75.5 x -7.22 x -19 x -174 x 59.6 x 34.3 x
Yield - - - - - - - -
Capitalization / Revenue 13.8 x 16.7 x 13.1 x 6.94 x 4.91 x 4.31 x 3.93 x 3.6 x
EV / Revenue 13.1 x 16 x 13.2 x 7.09 x 5.01 x 4.32 x 3.77 x 3.36 x
EV / EBITDA 37.8 x 56.5 x 46.8 x 45.9 x 46.2 x 41.6 x 26.7 x 18.6 x
EV / FCF 55.2 x 58.1 x 178 x 307 x 79.7 x 57.6 x 25.5 x 20.8 x
FCF Yield 1.81% 1.72% 0.56% 0.33% 1.26% 1.74% 3.92% 4.8%
Price to Book 10.6 x 11.6 x 5.56 x - - 3.31 x 3.08 x 2.81 x
Nbr of stocks (in thousands) 147,000 146,000 156,305 157,300 158,800 159,255 - -
Reference price 2 331.7 370.0 380.4 202.2 139.2 122.3 122.3 122.3
Announcement Date 1/29/20 2/11/21 2/10/22 2/7/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,543 3,239 4,526 4,584 4,504 4,515 4,955 5,413
EBITDA 1 1,231 916 1,277 708 488 468.5 701.5 976.8
EBIT 1 1,076 758 1,096 487 247 253.8 525.7 776.4
Operating Margin 30.37% 23.4% 24.22% 10.62% 5.48% 5.62% 10.61% 14.34%
Earnings before Tax (EBT) 1 1,118 856 884 -4,336 -1,117 -27.36 292.3 509
Net income 1 1,002 656 762 -4,404 -1,161 -136.9 286.3 522.8
Net margin 28.28% 20.25% 16.84% -96.07% -25.78% -3.03% 5.78% 9.66%
EPS 2 6.740 4.450 5.040 -28.00 -7.340 -0.7021 2.052 3.570
Free Cash Flow 1 842 891 337 106 283 338.5 732.5 872.7
FCF margin 23.77% 27.51% 7.45% 2.31% 6.28% 7.5% 14.78% 16.12%
FCF Conversion (EBITDA) 68.4% 97.27% 26.39% 14.97% 57.99% 72.25% 104.42% 89.34%
FCF Conversion (Net income) 84.03% 135.82% 44.23% - - - 255.81% 166.92%
Dividend per Share 2 - - - - - - - -
Announcement Date 1/29/20 2/11/21 2/10/22 2/7/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,108 1,198 1,223 1,162 1,115 1,083 1,087 1,176 1,119 1,122 1,051 1,105 1,143 1,202 1,156
EBITDA 1 307 196 263 194 159 90 80 143 154 113 73.24 92.12 128.5 158.7 98.42
EBIT 1 260 146 212 141 102 31 21 82 93 51 41.01 57.85 95.32 114.7 106
Operating Margin 23.47% 12.19% 17.33% 12.13% 9.15% 2.86% 1.93% 6.97% 8.31% 4.55% 3.9% 5.24% 8.34% 9.55% 9.18%
Earnings before Tax (EBT) 1 420 86 140 -637 -3,672 -168 -78 -89 -782 -168 -70.43 -90.65 35.03 65.4 39.57
Net income 1 317 112 86 -535 -3,816 -140 3 -234 -754 -176 -40.71 -43.07 18.24 41.43 22.4
Net margin 28.61% 9.35% 7.03% -46.04% -342.24% -12.93% 0.28% -19.9% -67.38% -15.69% -3.87% -3.9% 1.6% 3.45% 1.94%
EPS 2 2.080 0.7100 0.5500 -3.400 -24.26 -0.8900 0.0200 -1.480 -4.770 -1.110 -0.2060 -0.1700 0.1260 0.2525 0.1400
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/10/22 5/5/22 8/11/22 11/3/22 2/7/23 4/25/23 8/9/23 11/9/23 2/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 356 698 435 23.8 - -
Net Cash position 1 2,273 2,288 - - - - 770 1,285
Leverage (Debt/EBITDA) - - 0.2788 x 0.9859 x 0.8914 x 0.0508 x - -
Free Cash Flow 1 842 891 337 106 283 338 732 873
ROE (net income / shareholders' equity) 23.1% 14.3% 11.6% 3.88% 2.22% 2.69% 5.31% 8.81%
ROA (Net income/ Total Assets) 13.7% 8.91% 7.82% 2.45% 1.23% 1.27% 3.01% -
Assets 1 7,328 7,361 9,739 -180,020 -94,760 -10,811 9,513 -
Book Value Per Share 2 31.40 31.90 68.40 - - 37.00 39.70 43.60
Cash Flow per Share 2 7.050 7.300 3.610 2.500 3.030 2.720 6.020 7.420
Capex 1 209 189 208 286 195 236 240 261
Capex / Sales 5.9% 5.84% 4.6% 6.24% 4.33% 5.24% 4.85% 4.82%
Announcement Date 1/29/20 2/11/21 2/10/22 2/7/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Illumina, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.3 USD
Average target price
157.1 USD
Spread / Average Target
+28.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
ILLUMINA, INC. Stock Illumina, Inc.
-12.18% 19.47B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. ILMN Stock
  4. Financials Illumina, Inc.